何玉先 博士
主要研究领域: 病毒学
主要研究工作:
1.艾滋病病毒感染机制和免疫应答研究；
2.病毒中和抗体和疫苗、抗病毒药物研发。
主要代表论文：
1. He Y, Cheng J, Lu H, Li J, Hu J, Qi Z, Liu Z, Jiang S, Dai Q. Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains. Proc Natl Acad Sci U S A. 2008；105(42):16332-7. (Corresponding author)
2. He Y, Liu S, Li J, Lu H, Qi Z, Liu Z, Debnath AK, Jiang S. Conserved Salt-bridge between the N- and C-Terminal Heptad Repeat Regions of HIV-1 gp41 Core Structure Is Critical for Virus Entry and Inhibition. J Virol. 2008; 82(22): 11129-11139. (Corresponding author)
3. Xiao W, Du L, Liang C, Guan J, Jiang S, Lustigman S, He Y, Zhou Y. Evaluation of recombinant Onchocerca volvulus activation associated protein-1 (ASP-1) as a potent Th1-biased adjuvant with a panel of protein or peptide-based antigens and commercial inactivated vaccines. Vaccine. 2008;26(39):5022-9. (Corresponding author)
4. He Y, Chen J, Li J, Qi Z, Lu H, Dong M, Jiang S, Dai Q. Identification of a Critical Motif for the HIV-1 gp41 Core Structure: Implication for Designing Novel Anti-HIV Fusion Inhibitors. J Virol. 2008;82(13):6349-6358. (Corresponding author)
5. He Y, Xiao Y, Song H, Liang Q, Ju D, Chen X, Lu H, Jing W, Jiang S, Zhang L. Design and Evaluation of Sifuvirtide, a Novel HIV-1 Fusion Inhibitor. J Biol Chem. 2008;283(17):11126-11134. (First author)
6. Du L, Zhao G, He Y, Guo Y, Zheng BJ, Jiang S, Zhou Y.Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model.Vaccine. 2007;25(15):2832-2838. (Corresponding author)
7. He Y, Liu S, Jing W, Lu H, Cai D, Chin DJ, Debnath AK, Kirchhoff F, Jiang S. Conserved residue Lys574 in the cavity of HIV-1 Gp41 coiled-coil domain is critical for six-helix bundle stability and virus entry. J Biol Chem. 2007;282(35):25631-25639. (Corresponding author)
8. He Y, Li J, Du L, Yan X, Hu G, Zhou Y, Jiang S. Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine. Vaccine. 2006;24(26):5498-5508. (Corresponding author)
9. He Y. Immunogenicity of SARS-CoV: the receptor-binding domain of S protein is a major target of neutralizing antibodies. Adv Exp Med Biol. 2006;581:539-542. (Corresponding author)
10. He Y, Li J, Heck S, Lustigman S, Jiang S. Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design. J Virol. 2006 ;80(12):5757-5767. (Corresponding author)
11. He Y, Li J, Li W, Lustigman S, Farzan M, Jiang S. Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein. J Immunol. 2006;176(10):6085-6092. (Corresponding author)
12. He Y, Li J, Jiang S. A single amino acid substitution (R441A) in the receptor-binding domain of SARS coronavirus spike protein disrupts the antigenic structure and binding activity. Biochem Biophys Res Commun. 2006;344(1):106-113. (Corresponding author)
13. He Y, Jiang S. Vaccine design for severe acute respiratory syndrome coronavirus. Viral Immunol. 2005;18(2):327-332. (First author)
14. He Y, Zhou Y, Siddiqui P, Niu J, Jiang S. Identification of immunodominant epitopes on the membrane protein of the severe acute respiratory syndrome-associated coronavirus. J Clin Microbiol. 2005;43(8):3718-3726. (First author)
15. He Y, Zhu Q, Liu S, Zhou Y, Yang B, Li J, Jiang S. Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines. Virology. 2005;334(1):74-82. (First author)
16. He Y, Lu H, Siddiqui P, Zhou Y, Jiang S. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J Immunol. 2005;174(8):4908-4915. (First author)
17. He Y, Zhou Y, Wu H, Luo B, Chen J, Li W, Jiang S. Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines. J Immunol. 2004;173(6):4050-4057. (First author)
18. He Y, Zhou Y, Siddiqui P, Jiang S. Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry. Biochem Biophys Res Commun. 2004;325(2):445-52. (First author)
19. He Y, Zhou Y, Liu S, Kou Z, Li W, Farzan M, Jiang S. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem Biophys Res Commun. 2004;324(2):773-781. (First author)
20. He Y, Zhou Y, Wu H, Kou Z, Liu S, Jiang S. Mapping of antigenic sites on the nucleocapsid protein of the severe acute respiratory syndrome coronavirus. He Y, Zhou Y, Wu H, Kou Z, Liu S, Jiang S. J Clin Microbiol. 2004;42(11):5309-5314. (First author)
21. He Y, D'Agostino P, Pinter A. Analysis of the immunogenic properties of a single-chain polypeptide analogue of the HIV-1 gp120-CD4 complex in transgenic mice that produce human immunoglobulins. Vaccine. 2003;21(27-30):4421-4429. (First author)
22. He Y, Honnen WJ, Krachmarov CP, Burkhart M, Kayman SC, Corvalan J, Pinter A. Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci. J Immunol. 2002;169(1):595-605. (First author)